Completed PHASE4 INTERVENTIONAL 2-arm NCT00878878

Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).

A Phase 4, Placebo Controlled, Single-blind, Cross-over Safety Study to Evaluate the Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR) as Measured by Right Heart Catheterization

Sponsor: GE Healthcare

Conditions Pulmonary Hypertension

Interventions Dextrose Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)

Updated 9 times since 2017 Last updated: Jul 19, 2012 Started: Mar 31, 2009 Primary completion: Jul 31, 2010 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Pulmonary Hypertension, this trial is completed. The trial is conducted by GE Healthcare and has accumulated 9 data snapshots since 2009. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4

▶ Show 4 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GE Healthcare
ICON Clinical Research

Data source: GE Healthcare

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Elliott, United States